Matoke® Holdings Ltd is developing its patented Reactive Oxygen® technology as novel treatments which are much more than conventional antibiotics.

Reactive Oxygen® technology is a novel antimicrobial platform creating treatments for chronic and acute indications with potential for accelerated wound healing, biofilm penetration, tissue regeneration, immune system stimulation and potential efficacy against Gram-positive and Gram-negative pathogenic bacteria, as well as pathogenic fungi and viruses.

With the World Health Organisation predicting that millions may die due to global antimicrobial resistance (AMR), Reactive Oxygen® technology offers a potential solution to the global AMR threat which can help save lives.

People per year

die from AMR

0 million
by 2025

could die annually
without action


annual cost of AMR
to the NHS